IDH2 and central nervous system cancer: In particular, isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutation [40,41] and 1p/19q codeletion [42] have been recognized as promising predictive molecular markers, resulting in their inclusion in the 2016 World Health Organization (WHO) classification of gliomas [9].